Search
Madrigal Pharmaceuticals Inc
MDGLAdd to Watchlist
461.707USD
-31.404-6.37%
Market hours （ET）Quotes delayed by 15 min
10.64BMarket Cap
LossP/E TTM
More Details of Madrigal Pharmaceuticals Inc Company
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Madrigal Pharmaceuticals Inc Info
Ticker SymbolMDGL
Company nameMadrigal Pharmaceuticals Inc
IPO dateFeb 06, 2007
CEOSibold (Bill)
Number of employees528
Security typeOrdinary Share
Fiscal year-endFeb 06
Address200 Barr Harbor Drive, Suite 400
CityWEST CONSHOHOCKEN
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19428
Phone14043809263
Websitehttps://www.madrigalpharma.com/
Ticker SymbolMDGL
IPO dateFeb 06, 2007
CEOSibold (Bill)
Company Executives of Madrigal Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Director
Director
169.12K
+2.37%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
21.75K
+2.09%
Mr. Raymond Cheong, M.D., Ph.D.
Mr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.21K
+43.16%
Mr. Kenneth M. (Ken) Bate
Mr. Kenneth M. (Ken) Bate
Independent Director
Independent Director
1.91K
--
Ms. Shannon Kelley
Ms. Shannon Kelley
Executive Vice President, Chief Legal Counsel
Executive Vice President, Chief Legal Counsel
437.00
-280.09%
Ms. Carole A Huntsman
Ms. Carole A Huntsman
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
428.00
-64.02%
Dr. Rebecca A. Taub, M.D.
Dr. Rebecca A. Taub, M.D.
Director
Director
--
--
Mr. James M. Daly
Mr. James M. Daly
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Bill Sibold
Mr. Bill Sibold
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Paul A. Friedman, M.D.
Dr. Paul A. Friedman, M.D.
Director
Director
169.12K
+2.37%
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
21.75K
+2.09%
Mr. Raymond Cheong, M.D., Ph.D.
Mr. Raymond Cheong, M.D., Ph.D.
Independent Director
Independent Director
4.21K
+43.16%
Mr. Kenneth M. (Ken) Bate
Mr. Kenneth M. (Ken) Bate
Independent Director
Independent Director
1.91K
--
Ms. Shannon Kelley
Ms. Shannon Kelley
Executive Vice President, Chief Legal Counsel
Executive Vice President, Chief Legal Counsel
437.00
-280.09%
Ms. Carole A Huntsman
Ms. Carole A Huntsman
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
428.00
-64.02%
FAQs
Who are the top five shareholders of Madrigal Pharmaceuticals Inc?
The top five shareholders of Madrigal Pharmaceuticals Inc are: Dr. Paul A. Friedman, M.D.
How many institutions hold shares of Madrigal Pharmaceuticals Inc (MDGL)?
As of 2026Q1, 750 institutions hold shares of Madrigal Pharmaceuticals Inc, with a combined market value of approximately 24.02M, accounting for 104.16% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -163523.00.